{
    "clinical_study": {
        "@rank": "87248", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1a", 
                "arm_group_type": "Experimental", 
                "description": "MM-111 + Paclitaxel + Trastuzumab"
            }, 
            {
                "arm_group_label": "Arm 1b", 
                "arm_group_type": "Active Comparator", 
                "description": "Paclitaxel + Trastuzumab"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more\n      effective than paclitaxel and trastuzumab alone"
        }, 
        "brief_title": "A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "HER-2 Gene Amplification", 
            "Esophagus Cancer", 
            "Gastroesophageal Junction Cancer", 
            "Stomach Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Stomach Neoplasms", 
                "Esophageal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, open Label, Phase 2 Study of MM-111 and Paclitaxel withTrastuzumab in\n      Patients with HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE)\n      Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy.\n      Approximately 120 patients will be randomized in a 1:1 ratio between the experimental and\n      comparator arms."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have documentation of histologically or cytologically confirmed\n             metastatic or locally advanced adenocarcinoma of the distal esophagus, GE junction or\n             stomach\n\n          -  Patients must have documentation of histologically or cytologically confirmed HER2\n             expression\n\n          -  Patients must be \u226518 years of age\n\n          -  Patients must have ECOG PS of 0, 1, or 2\n\n          -  Patients must have adequate hematologic status, renal and hepatic function\n\n        Exclusion Criteria:\n\n          -  Patients with known hypersensitivity to any of the components of MM-111\n\n          -  Patients with a known history of hypersensitivity to paclitaxel or other drugs\n             formulated in Cremophor\u00ae EL\n\n          -  Patients with a known history of hypersensitivity to trastuzumab or any of its\n             components (group 1 patients only)\n\n          -  Patients with an active infection or with an unexplained fever >38.5\u00b0C"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01774851", 
            "org_study_id": "MM-111-13-02-04"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1a", 
                "description": "MM-111 (IV)", 
                "intervention_name": "MM-111", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm 1a", 
                    "Arm 1b"
                ], 
                "description": "Paclitaxel (IV)", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm 1a", 
                    "Arm 1b"
                ], 
                "description": "Trastuzumab (IV)", 
                "intervention_name": "Trastuzumab", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Paclitaxel", 
                "Trastuzumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "HER-2 Gene Amplification", 
            "Esophagus Cancer", 
            "Gastroesophageal Junction Cancer", 
            "Stomach Cancer", 
            "Her2 Positive", 
            "Her2+", 
            "Esophageal Cancer", 
            "Metastatic"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "contact": {
                "email": "joan.bloch@fccc.edu", 
                "last_name": "Joan Leahy", 
                "phone": "215-214-1472"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19111"
                }, 
                "name": "Fox Chase Cancer Center"
            }, 
            "investigator": {
                "last_name": "Crystal Denlinger, D", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy", 
        "overall_contact": {
            "email": "sfrye@merrimackpharma.com", 
            "last_name": "Sasha Frye", 
            "phone": "617-441-7667"
        }, 
        "overall_official": {
            "affiliation": "Merrimack Pharmaceuticals", 
            "last_name": "Akos Czibere, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression Free Survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "30 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01774851"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merrimack Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merrimack Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}